← Back to Search

Other

TNX-102 SL for Post-COVID Syndrome (PREVAIL Trial)

Phase 2
Waitlist Available
Research Sponsored by Tonix Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 14
Awards & highlights

PREVAIL Trial Summary

This trial will evaluate if TNX-102 SL 5.6 mg can help manage multi-site pain associated with Long COVID. The trial will last 14 weeks and compare TNX-102 SL 5.6 mg to a placebo.

Eligible Conditions
  • Post-COVID Syndrome
  • Coronavirus
  • COVID-19

PREVAIL Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 14
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 14 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Mean Pain Score
Secondary outcome measures
Patient Reported Outcomes Measurement Information System (PROMIS) score for sleep disturbance

Side effects data

From 2015 Phase 3 trial • 158 Patients • NCT02015234
13%
Sinusitis
10%
Fatigue
8%
Upper respiratory tract infection
5%
Constipation
5%
Somnolence
5%
Paraesthesia
3%
Glossodynia
1%
Intraductal proliferative breast lesion
1%
Ankle fracture
1%
Anxiety
1%
Hypoaesthesia oral
1%
Brain stem glioma
1%
Abdominal hernia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo - TNX-102 SL 2.8 mg
TNX-102 SL 2.8mg - TNX-102 SL 2.8 mg

PREVAIL Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: TNX-102 SL Tablet, 5.6 mgExperimental Treatment1 Intervention
1 x TNX-102 SL 2.8 mg Tablet taken sublingually each day at bedtime for 2 weeks, then 2 x TNX-102 SL 2.8 mg (5.6 mg) Tablet taken sublingually each day at bedtime for 12 weeks.
Group II: Placebo SL TabletPlacebo Group1 Intervention
1 x Placebo Tablet taken sublingually each day at bedtime for 2 weeks, then 2 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
TNX-102 SL
2019
Completed Phase 3
~1660

Find a Location

Who is running the clinical trial?

Tonix Pharmaceuticals, Inc.Lead Sponsor
29 Previous Clinical Trials
4,816 Total Patients Enrolled
Herb Harris, MD, PhDStudy DirectorTonix Pharmaceuticals
1 Previous Clinical Trials
685 Total Patients Enrolled

Media Library

Placebo SL Tablet (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05472090 — Phase 2
Post-COVID Syndrome Research Study Groups: TNX-102 SL Tablet, 5.6 mg, Placebo SL Tablet
Post-COVID Syndrome Clinical Trial 2023: Placebo SL Tablet Highlights & Side Effects. Trial Name: NCT05472090 — Phase 2
Placebo SL Tablet (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05472090 — Phase 2
~23 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top